Nektar's $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs
内克塔治疗公司完成3.25亿美元公开募股定价；Maze Therapeutics股价上涨；默克交易传闻；百时美施贵宝裁员

Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will fund “general corporate purposes,” including Phase 3 trials for its candidate rezpegaldesleukin in atopic dermatitis and alopecia areata. The drug, also known as rezpeg, failed a Phase 2b trial in alopecia areata last year. But data from the extension portion more or less met Wall Street analysts’ expectations, fueling Nektar’s ambitions. — Nicole DeFeudis
内克塔治疗公司定价3.25亿美元公开募股：这家湾区生物科技公司将以每股92美元出售约350万股股票。募集资金将用于“一般公司用途”，包括推进其候选药物rezpegaldesleukin在特应性皮炎和斑秃中的三期临床试验。该药物亦称rezpeg，去年在斑秃的二期b试验中失败。但其延长期数据大体符合华尔街分析师预期，推动了内克塔治疗公司的雄心。——Nicole DeFeudis。